GlassScriptPhysician profile
Ankur Mehta
NPI 1336241751
$73,307.15
in general payments reported to CMS, 2019-2025
24 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,873 · 2020: $6,070 · 2021: $9,467 · 2022: $14K · 2023: $9,622 · 2024: $14K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $3,918 · Food and Beverage: $843 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $675 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,034.50 |
| Travel and Lodging | $3,917.84 |
| Food and Beverage | $842.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $675.00 |
| Education | $248.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22,470.14 | 2019-2025 | Calquence, Tagrisso, Imfinzi |
| Abbvie INC. | $9,215.66 | 2020-2023 | |
| Gilead Sciences, INC. | $8,166.88 | 2022-2024 | Trodelvy |
| Adc Therapeutics America, INC. | $8,115.02 | 2023-2024 | |
| Genzyme Corporation | $4,125.73 | 2019-2021 | |
| Incyte Corporation | $3,300.00 | 2024 | |
| Exelixis INC. | $3,276.45 | 2019 | |
| Karyopharm Therapeutics INC. | $2,501.57 | 2023-2025 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $1,627.90 | 2020 | |
| Daiichi Sankyo INC. | $1,592.50 | 2022-2025 | Enhertu |
| Janssen Biotech, INC. | $1,419.81 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Astellas Pharma Global Development | $1,400.00 | 2022 | |
| Puma Biotechnology, INC. | $1,111.08 | 2019 | |
| Rigel Pharmaceuticals, INC. | $1,103.24 | 2020-2024 | Tavalisse, Rezlidhia |
| Tersera Therapeutics LLC | $900.00 | 2023-2025 | Margenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $800.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $757.50 | 2022 | |
| Leica Microsystems INC. | $675.00 | 2025 | |
| Becton, Dickinson and Company | $500.00 | 2021 | |
| Astellas Pharma US INC | $192.00 | 2023-2024 | |
| Nevro Corp. | $18.14 | 2024 | Senza |
| Pfizer INC. | $13.34 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.84 | 2023 | Fruzaqla |
| E.R. Squibb & Sons, L.L.C. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankur Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.